Trial Profile
A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics and Safety of EDP-305 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs EDP 305 (Primary) ; Itraconazole; Rifampicin
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary biliary cirrhosis
- Focus Pharmacokinetics
- Sponsors Enanta Pharmaceuticals
- 02 Nov 2017 Status changed from recruiting to completed.
- 14 Jul 2017 New trial record